405) describe an alternative method: the use of stable artificial antigen presenting ... used to stimulate T cells of any patient of a given human leukocyte antigen (HLA) type.

A variety of immune cell types contribute to disease in individuals ... examining how recent basic research implicates the antigen-presenting cell in this disease. In our 'Bedside to Bench ...

With every bite of food we take, our intestinal immune system must make a big decision. Tasked with defending us from foreign pathogens, these exquisitely sensitive cells somehow distinguish friend ...

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more ...

Seismic Therapeutic has dosed the first healthy participant cohort in the randomised Phase I trial of bifunctional antibody S ...

With every bite of food we take, our intestinal immune system must make a big decision. Tasked with defending us from foreign pathogens, these exquisitely sensitive cells somehow distinguish friend ...

When they cocultured both types of APCs with naïve T cells ... “So, it's a compartmentalization of dietary versus pathogen-derived antigens by different antigen-presenting cells.” Canesso said this ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...